T2 Biosystems, Inc. (NASDAQ:TTOO) Q4 2022 Earnings Call Transcript

Page 3 of 3

John Sperzel: And Kyle, I’ll just add to that. At the top end of our guide in Sepsis and related product revenue, which is our core business. The $13 Million would represent a 55% increase over what we achieved In 2022. And keep in mind, in that guidance, there is no T2Lyme and there is also no T2Biothreat.

Kyle Mikson: Okay. And there’s no COVID too, right in that product revenue guidance?

John Sperzel: That’s correct.

Kyle Mikson: Perfect. All right, fantastic. Thanks so much, guys. I appreciate it.

John Sprague: Thank you.

John Sperzel: Thank you, Kyle.

Operator: Thank you. That concludes our Q&A session. I would now hand the conference back to John Sperzel, Chairman and CEO for closing remarks. Please go ahead.

John Sperzel: Thank you all for joining our fourth quarter 2022 and full-year 2022 earnings call. We appreciate your support, and we look forward to our Q1 earnings call. Thank you very much. Have a great day.

Operator: Thank you, everyone. This concludes today’s event. You may disconnect at this time and have a wonderful day. Thank you for your participation.

Follow T2 Biosystems Inc. (NASDAQ:TTOO)

Page 3 of 3